Nice try shorty, er honkass. Company blows away 2014 (current) guidance even if injectables were pulled pending IND. It's a non issue
The findings also reveal that the projected launch of APR Applied Pharma Research/tesa Labtec's Zolmitriptan RapidFilm (zolmitriptan oral dispersible film) in additional markets and the launch of four novel triptan reformulations in the United States through 2017 will partially offset generic erosion of this drug class. Emerging reformulations include NuPathe's sumatriptan transdermal patch Zecuity, IntelGenx/RedHill Biopharma's rizatriptan oral film (INT-0008), Avanir Pharmaceuticals/OptiNose's sumatriptan intranasal powder (AVP-825) and Suda's sumatriptan oral spray (SUD-001). Although these niche products are forecast to garner modest patient shares, their combined sales will contribute nearly 15 percent market share at end of our forecast period.
Umm, you do understand that the FDA decision has no bearing on MDXG's near term prospects? It does not affect the vast majority of current sales
Jason is a pretty smart bio analyst
@JNapodano: Wow, $OSIR CEO to step-down. Comes 3 days after CMS decision on wound care reimbursement ensures Grafix will be commercial failure
You do realize that you are only focused on a part of the business right? Not the injectables, though a study may have to be done for those. Too bad Dr. James Andrews can't post here regarding his experiences. You do know who Dr. Andrews is? Happens to also be chief medical adviser on advisory board at MDXG.
Thanks Dr. Hursh. And to the board, Dr. Hursh is "legit". You can google him for his background
All SA does is provide a forum for any ying yang who fancies himself or herself as an analyst to have a forum for feeling important. Tons of garbage articles there and some good ones. No real screening process or editing by SA..from my perspective the people running that site are worthless. So, there is some good information that can be found from articles there, just have to be able to vet the garbage.
Pretty sure a doc or two has posted here. And, as for the ambulance chasers, except for the dimwits who freaked out and sold when the FDA news broke, not much in the way of losses. For most of us who understood the relevant irrelevancy of the FDA letter, just presented a great opportunity
I get them from our Bloomberg terminal. Numbers are from Symphony, one of the two main providers, IMS being the other one
Company said they can hit guidance next year with 2.5% market share. That seems low considering the strength of the product. Numbers could go up exponentially
Give me a break. I am more deeply involved in the market than all of you folks combined, and, I do not say that to "brag". Just stating a fact. If it makes you feel better to believe that your investment is down due to some conspiracy by "market makers' or manipulation as opposed to the fact that no one is interested is a spec play with no sales, no cash where management felt the need to mention bankruptcy as a possibility next quarter, go right ahead.